Continued Poor Survival in Metastatic Uveal Melanoma: Implications for Molecular Prognostication, Surveillance Imaging, Adjuvant Therapy, and Clinical Trials

Douglas B Johnson^{1

2}, Anthony B Daniels^{1

3

4

5}

Affiliations

¹ Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
² Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
³ Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee.
⁴ Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
⁵ Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee.

Comment

Douglas B Johnson et al. JAMA Ophthalmol. 2018.

. 2018 Sep 1;136(9):986-988.

doi: 10.1001/jamaophthalmol.2018.1813.

Douglas B Johnson^{1

2}, Anthony B Daniels^{1

3

4

5}

¹ Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee.
² Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
³ Department of Ophthalmology and Visual Sciences, Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, Tennessee.
⁴ Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
⁵ Program in Cancer Biology, Vanderbilt University, Nashville, Tennessee.

No abstract available

Comment on

Survival Rates in Patients After Treatment for Metastasis From Uveal Melanoma.
Lane AM, Kim IK, Gragoudas ES. Lane AM, et al. JAMA Ophthalmol. 2018 Sep 1;136(9):981-986. doi: 10.1001/jamaophthalmol.2018.2466. JAMA Ophthalmol. 2018. PMID: 29955797 Free PMC article.